IMI Call for Proposals with Focus on Alzheimer's Disease, Diabetes, Patient Involvement

The Innovative Medicines Initiative (IMI)The Innovative Medicines Initiative (IMI) has launched its 5th Call for proposals under the IMI 2 programme. IMI 2 - Call 5 has a total budget of €95 million and features 6 topics. Of these, four focus on different aspects of Alzheimer's disease, one focuses on diabetic kidney disease, and one addresses patient input on assessments of the benefits and risks of medicines.

Four topics focus on Alzheimer's disease, an area where there is an urgent need for new treatments.

Inflammation and Alzheimer's disease: This topic aims to identify new drug targets for Alzheimer's disease focusing on two proteins (called TREM2 and CD33) that are linked to inflammation and are thought to affect people's risk of developing Alzheimer's disease.

Amyloid imaging biomarkers: Many people with Alzheimer's disease have clumps of protein called amyloid plaques in their brains. This topic will seek to review the usefulness of knowing a patient's amyloid brain status for diagnosis and treatment, and determine the value of amyloid imaging in drug development.

Alzheimer's disease and patient engagement: Dementia researchers are increasingly focusing their efforts on finding ways to prevent the onset of Alzheimer's symptoms in the first place. The goal of this topic is to identify the most effective ways of identifying and engaging with people who are in the very earliest stages of the disease. This will add to our understanding of the early stages of the disease, help patients access support from early on in their disease, and facilitate recruitment for clinical trials.

Apolipoprotein E (ApoE) biology: People who have the ApoE4 gene are at greater risk of developing Alzheimer's disease. This topic will explore precisely how ApoE4 influences the development of Alzheimer's disease and pave the way for new treatment strategies for Alzheimer's and better identification of individuals at greatest risk for developing the disease.

The topic on diabetes is designed to address the need for biological markers of diabetic kidney disease (DKD). DKD is a common complication of diabetes; the biological markers will add to our understanding of DKD and will advance the development and evaluation of new treatments for DKD.

In line with IMI's goal of boosting patient involvement in research, the Call also features a topic that will explore when and how best to gain patients' input on the benefits and risks of medicines, at all stages of the drug development life cycle, to inform decision-making processes.

Irene Norstedt, IMI Acting Executive Director commented: "With the launch of this Call for proposals, IMI once again affirms its commitment to tackling some of the biggest public health challenges facing Europe today - Alzheimer's disease and diabetes. At the same time, the fact that we have two topics dedicated to patient engagement underlines IMI's role as a platform for multi-stakeholder collaboration."

The deadline for submitting short proposals is 13 October 2015.

Half of the Call's budget (€47.5 million) comes from the European Commission through the Horizon 2020 programme for research and innovation. The other half will be contributed by EFPIA companies involved in the projects as well as other Associated Partners. These groups do not receive any funding from IMI, but contribute 'in kind' with their researchers' time, access to resources and equipment, etc.

For further information on the new Call for proposals, including all topic texts and details of how to apply, can be found on the IMI website:
http://www.imi.europa.eu/content/stage-1-16

About the Innovative Medicines Initiative
The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.

IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Through the IMI 2 programme, IMI has a budget of €3.3 billion for the period 2014-2024. Half of this comes from the EU's research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects 'in kind', for example by donating their researchers' time or providing access to research facilities or resources.

Most Popular Now

Philips Foundation 2024 Annual Report: E…

Marking its tenth anniversary, Philips Foundation released its 2024 Annual Report, highlighting a year in which the Philips Foundation helped provide access to quality healthcare for 46.5 million people around...

New AI Transforms Radiology with Speed, …

A first-of-its-kind generative AI system, developed in-house at Northwestern Medicine, is revolutionizing radiology - boosting productivity, identifying life-threatening conditions in milliseconds and offering a breakthrough solution to the global radiologist...

Scientists Argue for More FDA Oversight …

An agile, transparent, and ethics-driven oversight system is needed for the U.S. Food and Drug Administration (FDA) to balance innovation with patient safety when it comes to artificial intelligence-driven medical...

New Research Finds Specific Learning Str…

If data used to train artificial intelligence models for medical applications, such as hospitals across the Greater Toronto Area, differs from the real-world data, it could lead to patient harm...

Giving Doctors an AI-Powered Head Start …

Detection of melanoma and a range of other skin diseases will be faster and more accurate with a new artificial intelligence (AI) powered tool that analyses multiple imaging types simultaneously...

AI Agents for Oncology

Clinical decision-making in oncology is challenging and requires the analysis of various data types - from medical imaging and genetic information to patient records and treatment guidelines. To effectively support...

Patients say "Yes..ish" to the…

As artificial intelligence (AI) continues to be integrated in healthcare, a new multinational study involving Aarhus University sheds light on how dental patients really feel about its growing role in...

Brains vs. Bytes: Study Compares Diagnos…

A University of Maine study compared how well artificial intelligence (AI) models and human clinicians handled complex or sensitive medical cases. The study published in the Journal of Health Organization...

'AI Scientist' Suggests Combin…

An 'AI scientist', working in collaboration with human scientists, has found that combinations of cheap and safe drugs - used to treat conditions such as high cholesterol and alcohol dependence...

Start-ups in the Spotlight at MEDICA 202…

17 - 20 November 2025, Düsseldorf, Germany. MEDICA, the leading international trade fair and platform for healthcare innovations, will once again confirm its position as the world's number one hotspot for...